Photo by matmacq from unsplash
Secondary sclerosing cholangitis (SSC) is a rare disease that is associated with various etiologies. Recent development of immune checkpoint inhibitors demonstrates efficacy in the treatment of various malignancies; however, these… Click to show full abstract
Secondary sclerosing cholangitis (SSC) is a rare disease that is associated with various etiologies. Recent development of immune checkpoint inhibitors demonstrates efficacy in the treatment of various malignancies; however, these inhibitors can also cause immune-related adverse events, including inflammatory manifestations. We are the first group of researchers to report on pembrolizumab-induced SSC through imaging and histological analyses. This article is protected by copyright. All rights reserved.
Journal Title: Hepatology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!